Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
17 results
D1.422 - Characterization of provocation-induced changes in transcription factors in the nasal mucosa of birch pollen-allergic and non-allergic individuals
D1.425 - Impact of Early Postnatal Administration of Escherichia coli O83:K24:H31 on Immune System Maturation and Gut Barrier Function
D1.424 - Single-cell transcriptomic profiling of allergen-restimulated PBMCs reveals innate immune activation in equine insect bite hypersensitivity
D1.430 - Extracellular vesicles isolated after cholinergic urticaria challenge carry MRGPRX2 and induce pro-inflammatory mast cell responses
D1.431 - Distinct Immunophenotypic Signatures in Pediatric Allergic Disease: Clinical Utility of Methylation qPCR–Based Epigenetic TBNK Profiling
D1.433 - DNA Ligase I Deficiency Masquerading as CVID-Like Phenotype: Implications for Long-Term Surveillance
D1.434 - Phenotyping Common Variable Immunodeficiency by Immune Dysregulation at Diagnosis: A Descriptive Comparison of Baseline Clinical and Laboratory Findings
D1.436 - Transfusion-Related Acute Lung Injury (TRALI) following plasma transfusion: A case report
D2.475 - Treatment delay and likelihood of remission on omalizumab in chronic spontaneous urticaria: a real-world observational study
D2.465 - Omalizumab Enhances Safety and Supports Completion of Oral Immunotherapy in High-Risk Patients
D2.466 - More options for the treatment of Chronic Spontaneous Urticaria: Tezepelumab
D2.467 - Management of Netherton syndrome and hereditary angioedema with concurrent biologic therapy: a novel case
D2.468 - Real-world effectiveness and safety of dupilumab in pediatric atopic dermatitis: a retrospective cohort study
D2.469 - Pre-switch perceptions of omalizumab biosimilar prefilled pen in pediatric allergy: a cross-sectional survey
D2.472 - Immunology Innovation Program: Developing Antibodies Against Novel Targets Through Co-creation
D2.474 - Use of Dupilumab as treatment for Eosinophilic Enteritis: a case report
D2.476 - Mepolizumab Enables Meaningful Real-World Improvements in SNOT-22 and Smell Dysfunction in Chronic Rhinosinusitis with Nasal Polyps: Post Hoc Analysis of REALITI-N at 3 and 6 Months
Download the app
The congress at your fingertips
Available on
Download